Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients

Daniele Lilleri, Giuseppe Gerna

Research output: Contribution to journalReview articlepeer-review

Abstract

Human cytomegalovirus (HCMV) represents the major viral complication after hematopoietic stem cell transplantation. HCMV infection may be controlled by the reconstituting immune system and remain subclinical or can lead to severe systemic and/or organ disease (mainly pneumonia and gastroenteritis) when immune reconstitution is delayed or impaired. In order to prevent the occurrence of HCMV disease, a prompt diagnosis of HCMV infection is mandatory. The adoption of pre-emptive therapy strategies guided by virological monitoring dramatically reduced the occurrence of HCMV disease. However, late-onset end-organ disease may occur in some patients with apparent immune reconstitution. In the near future, introduction of immunological monitoring and immunotherapies could markedly improve management of HCMV infection.

Original languageEnglish
Pages (from-to)1135-1149
Number of pages15
JournalImmunotherapy
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Keywords

  • hematopoietic stem cell transplantation
  • human cytomegalovirus
  • immune reconstitution
  • pre-emptive therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint Dive into the research topics of 'Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients'. Together they form a unique fingerprint.

Cite this